CMRX - キメリックス （Chimerix Inc.） キメリックスCMRXのチャート
CMRXの企業情報
| symbol | CMRx |
|---|---|
| 会社名 | Chimerix Inc. （キメリックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 チメリックス（Chimerix Inc.）はバイオ医薬品会社である。同社は未充足の医療ニーズに対処する薬品の発見、開発、商業化を行う。同社のリード化合物brincidofovirは天然痘、アデノウイルス（AdV）、およびヒトヘルペスウイルスを含むデオキシリボ核酸（DNA）ウイルスの治療と予防のための経口および静脈内（IV）製剤として開発中である。同社はノロウイルスの予防、治療ためのCMX521の開発を進める。さらに、同社は治療法の乏しいあるいはないウイルス標的に集中するアクティブな発見プログラムがある。Brincidofovirは人間に感染できる5つのファミリーの二本鎖デオキシリボ核酸（dsDNA）ウイルスすべてに対してスペクトル抗ウイルス活性を示した研究用経口ヌクレオチド類似体である。brincidofovirの経口、IV製剤は活性な抗ウイルスをウイルス複製部位に直接送達する開発階段中である。 キメリックスは、米国のバイオ医薬品会社。経口抗ウイルス薬を発見、開発、商品化する。同社は独自の脂質技術を利用し、2種類のヌクレオチド化合物を開発。「Brincidofovir (CMX001)」は第3相臨床段階にある。「CMX157」は第1相臨床試験を終えた後、メルク・シャ―プ・アンド・ド―ム社へライセンス供与した。 Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The company's three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients. |
| 本社所在地 | 2505 Meridian Parkway Suite 100 Durham NC 27713 USA |
| 代表者氏名 | Martha J. Demski マーサ・J・デムスキー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 919-806-1074 |
| 設立年月日 | 36617 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 82人 |
| url | www.chimerix.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cmrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -75.05300 |
| 終値（lastsale） | 3.84 |
| 時価総額（marketcap） | 184420899.84 |
| 時価総額 | 時価総額（百万ドル） 172.89460 |
| 売上高 | 売上高（百万ドル） 4.72400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -1.86840 |
| 当期純利益 | 当期純利益（百万ドル） -74.98900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Chimerix Inc revenues increased 13% to $2M. Net loss increased 12% to $38.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 21% to $25.2M (expense) General and administrative increase of 7% to $8.8M (expense). |
CMRXのテクニカル分析
CMRXのニュース
Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference 2021/09/07 11:00:00 Intrado Digital Media
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix and Mike Andriole, Chief Financial and Business Officer of Chimerix, will participate in a pre-recorded fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference that will be made available on Monday, September 13, 2021 at 7:00 a.m. ET.
Rhabdoid Tumor Treatment Market SWOT Analysis, Key Indicators, Forecast 2028 : Takeda Pharmaceutical Company Limited, Chimerix, Epizyme, Inc., Vyriad, DNAtrix, Lantern Pharma, Inc., and Pfizer Inc 2021/08/31 09:57:38 OpenPR
Global rhabdoid tumor treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.10% in the above mentioned forecast
Chimerix, Inc. (CMRX) CEO Mike Sherman on Q2 2021 Results - Earnings Call Transcript 2021/08/08 08:24:03 Seeking Alpha
Earnings news: Duke Energy, CommScope, BioCryst, Chimerix | WRAL TechWire 2021/08/05 12:05:49 WRAL TechWire
Duke Energy, CommScope and two biotech firms in the Triangle report their financials as earnings season continues. Here''s the latest: Duke Energy CHARLOTTE -
Thursday 7/1 Insider Buying Report: CMRX, FOR 2021/07/01 17:50:13 One News Page
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let''s look at two noteworthy recent insider buys.
Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX) 2021/06/08 11:15:08 Smarter Analyst
Maxim Group analyst Naureen Quibria reiterated a Buy rating on Chimerix (CMRX) yesterday and set a price target of $20.00. The post Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX) appeared first on Smarter Analyst .
FDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patients 2021/06/08 10:28:15 FiercePharma
FDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patients ntaylor Tue, 06/08/2021 - 06:28
H.C. Wainwright Maintains Their Buy Rating on Chimerix (CMRX) 2021/06/07 10:06:31 Smarter Analyst
H.C. The post H.C. Wainwright Maintains Their Buy Rating on Chimerix (CMRX) appeared first on Smarter Analyst .
Chimerix (CMRX) Gets a Buy Rating from JonesTrading 2021/06/04 18:45:24 Smarter Analyst
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Chimerix (CMRX), with a price target of $14.00. The post Chimerix (CMRX) Gets a Buy Rating from JonesTrading appeared first on Smarter Analyst .
Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX) 2021/06/08 11:15:08 Smarter Analyst
Maxim Group analyst Naureen Quibria reiterated a Buy rating on Chimerix (CMRX) yesterday and set a price target of $20.00. The post Maxim Group Sticks to Their Buy Rating for Chimerix (CMRX) appeared first on Smarter Analyst .
FDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patients 2021/06/08 10:28:15 FiercePharma
FDA approves Chimerix''s oral suspension smallpox antiviral, giving treatment option to dysphagic patients ntaylor Tue, 06/08/2021 - 06:28
H.C. Wainwright Maintains Their Buy Rating on Chimerix (CMRX) 2021/06/07 10:06:31 Smarter Analyst
H.C. The post H.C. Wainwright Maintains Their Buy Rating on Chimerix (CMRX) appeared first on Smarter Analyst .
Chimerix (CMRX) Gets a Buy Rating from JonesTrading 2021/06/04 18:45:24 Smarter Analyst
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Chimerix (CMRX), with a price target of $14.00. The post Chimerix (CMRX) Gets a Buy Rating from JonesTrading appeared first on Smarter Analyst .